ESR1 and cancer: In addition to confirming the clear association of DSCAM-AS1 expression in cancer vs normal breast, in ERα+ vs ERα-, and in luminal vs triple-negative subtypes, we observed also higher DSCAM-AS1 expression in tumors that are not metastatic vs metastatic, although not all the metastatic sites were considered in these studies.